Extended Low-Dose Apixaban After Provoked VTE: Marc Carrier Spotlights Major NEJM Results
Marc Carrier, Professor at Ottawa Hospital Research Institute, has posted on X:
”New in NEJM:
In patients with provoked VTE + enduring risk factors, extended low-dose apixaban (2.5 mg bid ×12 months): reduced recurrent VTE risk by nearly 90% (1.3% vs 10.0%): HR 0.13
Major bleeding was rare (1 pt).”
Find the full study here.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, and Samuel Z. Goldhaber
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 09:15Reza Bavarsad Shahripour: When the Ophthalmic Artery Tells the Story of the Carotid
-
Mar 6, 2026, 09:13Louise St. Germain Bannon: Advancing Thrombosis and Hemostasis Through a Global Community
-
Mar 6, 2026, 09:06Kathleen Freson: Protein C Deficiency as a Genetic Modifier of Severe Haemophilia A
-
Mar 5, 2026, 17:48Estelle Carminita։ What If the Origin of Platelet Dysfunction Starts in the Bone Marrow
-
Mar 5, 2026, 17:43Pierre Sabouret: The Best Antithrombotic Strategy in Patients with Atherosclerotic Stroke and AF
-
Mar 5, 2026, 17:37John Abraham։ The Role of Diagnostic Splenectomy in Unexplained Splenomegaly
-
Mar 5, 2026, 17:31Fayad Al-Haimus: Key Themes from the New 2026 AHA/ACC Guideline for Acute PE
-
Mar 5, 2026, 16:56From Chronic Pain with Every Step to Exercising Every Day – EHC
-
Mar 5, 2026, 15:51Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies